176 related articles for article (PubMed ID: 26082469)
41. Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington's Disease Progression.
Sawant N; Reddy PH
J Alzheimers Dis; 2019; 72(s1):S177-S191. PubMed ID: 31744007
[TBL] [Abstract][Full Text] [Related]
42. Systematic analysis of GSK-3 signaling pathways in aging of cerebral tissue.
Drulis-Fajdasz D; Rakus D; Wiśniewski JR; McCubrey JA; Gizak A
Adv Biol Regul; 2018 Aug; 69():35-42. PubMed ID: 29958836
[TBL] [Abstract][Full Text] [Related]
43. A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain.
de Cristóbal J; Garcia-Garcia L; Delgado M; Pozo MA; Medina M
Curr Alzheimer Res; 2014 Feb; 11(2):175-81. PubMed ID: 23905999
[TBL] [Abstract][Full Text] [Related]
44. The energetics of Huntington's disease.
Browne SE; Beal MF
Neurochem Res; 2004 Mar; 29(3):531-46. PubMed ID: 15038601
[TBL] [Abstract][Full Text] [Related]
45. Brain Diffusivity and Structural Changes in the R6/2 Mouse Model of Huntington Disease.
Vorisek I; Syka M; Vargova L
J Neurosci Res; 2017 Jul; 95(7):1474-1484. PubMed ID: 27726161
[TBL] [Abstract][Full Text] [Related]
46. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.
Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM
J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161
[TBL] [Abstract][Full Text] [Related]
47. Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.
Larkin PB; Muchowski PJ
J Huntingtons Dis; 2012; 1(1):107-18. PubMed ID: 23097680
[TBL] [Abstract][Full Text] [Related]
48. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach.
Hay DG; Sathasivam K; Tobaben S; Stahl B; Marber M; Mestril R; Mahal A; Smith DL; Woodman B; Bates GP
Hum Mol Genet; 2004 Jul; 13(13):1389-405. PubMed ID: 15115766
[TBL] [Abstract][Full Text] [Related]
49. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
Palomo V; Martinez A
Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
[TBL] [Abstract][Full Text] [Related]
50. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.
Kim J; Amante DJ; Moody JP; Edgerly CK; Bordiuk OL; Smith K; Matson SA; Matson WR; Scherzer CR; Rosas HD; Hersch SM; Ferrante RJ
Biochim Biophys Acta; 2010; 1802(7-8):673-81. PubMed ID: 20460152
[TBL] [Abstract][Full Text] [Related]
51. Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington's disease.
Patassini S; Begley P; Reid SJ; Xu J; Church SJ; Curtis M; Dragunow M; Waldvogel HJ; Unwin RD; Snell RG; Faull RL; Cooper GJ
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):161-6. PubMed ID: 26522227
[TBL] [Abstract][Full Text] [Related]
52. Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice.
Sorolla MA; Rodríguez-Colman MJ; Vall-Llaura N; Vived C; Fernández-Nogales M; Lucas JJ; Ferrer I; Cabiscol E
Metab Brain Dis; 2016 Jun; 31(3):579-86. PubMed ID: 26666246
[TBL] [Abstract][Full Text] [Related]
53. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.
Gómez-Sintes R; Lucas JJ
J Clin Invest; 2010 Jul; 120(7):2432-45. PubMed ID: 20530871
[TBL] [Abstract][Full Text] [Related]
54. Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.
Naseri NN; Xu H; Bonica J; Vonsattel JP; Cortes EP; Park LC; Arjomand J; Gibson GE
J Neuropathol Exp Neurol; 2015 Jun; 74(6):527-37. PubMed ID: 25978848
[TBL] [Abstract][Full Text] [Related]
55. Shared and oppositely regulated transcriptomic signatures in Huntington's disease and brain ischemia confirm known and unveil novel potential neuroprotective genes.
Yildirim F; Foddis M; Blumenau S; Müller S; Kajetan B; Holtgrewe M; Kola V; Beule D; Sassi C
Neurobiol Aging; 2021 Aug; 104():122.e1-122.e17. PubMed ID: 33875290
[TBL] [Abstract][Full Text] [Related]
56. Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.
St-Cyr S; Child DD; Giaime E; Smith AR; Pascua CJ; Hahm S; Saiah E; Davidson BL
PLoS One; 2022; 17(8):e0273710. PubMed ID: 36037192
[TBL] [Abstract][Full Text] [Related]
57. Transgenic Animal Models of Huntington's Disease.
Yang SH; Chan AW
Curr Top Behav Neurosci; 2011; 7():61-85. PubMed ID: 21225414
[TBL] [Abstract][Full Text] [Related]
58. What's wrong with my mouse cage? Methodological considerations for modeling lifestyle factors and gene-environment interactions in mice.
Mo C; Renoir T; Hannan AJ
J Neurosci Methods; 2016 May; 265():99-108. PubMed ID: 26279343
[TBL] [Abstract][Full Text] [Related]
59. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.
Hodges A; Hughes G; Brooks S; Elliston L; Holmans P; Dunnett SB; Jones L
Genes Brain Behav; 2008 Apr; 7(3):288-99. PubMed ID: 17696994
[TBL] [Abstract][Full Text] [Related]
60. Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains.
Ratovitski T; Chaerkady R; Kammers K; Stewart JC; Zavala A; Pletnikova O; Troncoso JC; Rudnicki DD; Margolis RL; Cole RN; Ross CA
J Proteome Res; 2016 Sep; 15(9):3266-83. PubMed ID: 27486686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
